RecruitingShingles
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Eligible age
All ages
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Sponsor: Loyola University
You may qualify if…
- ✓ Age ≥18 years
- ✓ ≥ 12 months and ≤ 36 months post-AlloSCT
- ✓ Donor sources: matched related, matched unrelated, cord blood
- ✓ Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.
- ✓ Any conditioning regimen
- ✓ Any planned immunosuppressive prophylactic regimen
- ✓ Patients with chronic graft-versus-host disease on stable immunosuppression
- ✓ Ability to understand and the willingness to sign a written informed consent.
You may not qualify if…
- ✕ Patients who had zoster after an allogeneic transplant and prior to enrollment
- ✕ Patients who are currently pregnant
- ✕ History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.
- ✕ Patients who have had a relapse of their primary hematological disease
- ✕ Previous allogeneic stem cell transplantation
- ✕ Acute disease at the time of vaccination
- ✕ Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.
Where it's recruiting
Illinois
Maywood
Source: ClinicalTrials.gov · NCT05554068 · last updated 2023-03-08